| Market Capitalization (Millions $) |
2,222 |
| Shares
Outstanding (Millions) |
103 |
| Employees |
178 |
| Revenues (TTM) (Millions $) |
158 |
| Net Income (TTM) (Millions $) |
-193 |
| Cash Flow (TTM) (Millions $) |
72 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Day One Biopharmaceuticals is a privately held, clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company was founded in 2018 by Jeremy Bender, M.D., Ph.D., a former partner at Deerfield Management, and Josh Resnick, CEO of the oncology company, Outpost Medicine. Day One Biopharmaceuticalse primary focus is on developing precision medicines for patients with cancer and autoimmune disorders. The company received $60 million in funding in a Series A round led by ARCH Venture Partners and includes Pfizer Ventures, Lux Capital, GV, and Alexandria Venture Investments.
One of the main reasons for the company's founding is to bring a more personalized approach to cancer treatment. Day One Biopharmaceuticals concentrates on identifying targets that are highly expressed in specific subtypes of cancer and developing highly selective drugs that zero in on those targets. This is done using its proprietary platform, which combines single-cell sequencing, proteomics, and artificial intelligence (AI) techniques to identify and focus on targets that are present only on cancer cells, leaving healthy cells unharmed.
Another area of focus for Day One Biopharmaceuticals is autoimmune diseases since the platform it uses to identify drug targets could also find targets on cells that are driving autoimmune disorders. The company's pipeline starts with two oncology programs targeting the RAS and Myc cancer pathways, both of which are known for their complexity and elusiveness in therapeutic targeting. Day Onees scientific approach is expected to be highly effective, given the complexity of these developmental pathways. Other programs it is working on target novel metabolic pathways in cancer cells as well as cytokine targets and immune cells for autoimmune disease.
In summary, Day One Biopharmaceuticals is an innovative, privately held clinical-stage biopharmaceutical company with a mission to develop highly selective drugs using its proprietary AI-based platform for cancer and autoimmune diseases. With significant funding from a range of investors, the company is well-positioned to make progress in its pipeline of novel therapies.
Company Address: 1800 Sierra Point Parkway Brisbane 94005 CA
Company Phone Number: 484-0899 Stock Exchange / Ticker: NASDAQ DAWN
|
0.000%
2.88% 